Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in&nbsp;tamoxifen‑resistant breast cancer cells

Cai,Jiaqin; Sun,Hong; Zheng,Bin; Xie,Mumu; Xu,Chenxia; Zhang,Guifeng; Huang,Xuhui; Zhuang,Jie

doi:10.3892/mmr.2020.11651

Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells

Authors:
- Jiaqin Cai
- Hong Sun
- Bin Zheng
- Mumu Xie
- Chenxia Xu
- Guifeng Zhang
- Xuhui Huang
- Jie Zhuang
View Affiliations

Affiliations: Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: November 3, 2020 https://doi.org/10.3892/mmr.2020.11651
Article Number: 13
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The H19 long non‑coding RNA is involved in the development of tamoxifen resistance in breast cancer. However, the relationship between H19 and the metastatic potential and treatment options for tamoxifen‑resistant (TAMR) breast cancer is not completely understood. Curcumin inhibits cellular proliferation, migration and invasiveness in several cancer types, including pancreatic cancer, breast cancer and chronic myeloid leukemia. The present study aimed to investigate the role of H19 in MCF‑7/TAMR cell epithelial‑mesenchymal transition (EMT), migration and invasiveness, and to assess the ability of curcumin to inhibit H19‑mediated effects. Reverse transcription‑quantitative PCR and western blot analysis were conducted to detect the gene or protein expression. Cell Counting Kit‑8, wound healing and Transwell invasion assays were performed to estimate the capabilities of cell viability, invasion and migration. H19 overexpression enhanced MCF‑7/TAMR cell EMT, invasion and migration by upregulating Snail. Furthermore, curcumin notably decreased the expression levels of epithelial marker E‑cadherin and markedly increased the expression levels of mesenchymal marker N‑cadherin in MCF‑7/TAMR cells compared with the control group. In addition, following treatment with curcumin for 48 h, H19 expression was decreased in a dose‑dependent manner. Moreover, curcumin treatment for 48 h significantly attenuated H19‑induced alterations in N‑cadherin and E‑cadherin expression levels. Curcumin also prevented H19‑induced invasion and migration. The present study indicated that H19 may serve as a promoting factor of EMT, invasion and migration in MCF‑7/TAMR cells, suggesting that curcumin may prevent H19‑associated metastasis. Therefore, curcumin may serve as a promising therapeutic drug for patients with TAMR breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, et al: Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: A systematic review and meta-analysis. Breast. 33:104–108. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zhang Y and Liu Y: Endocrine therapy for breast cancer: Past and present. Zhonghua Yi Shi Za Zhi. 45:28–32. 2015.(In Chinese). PubMed/NCBI
4	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), ; Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
5	Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 32:2255–2269. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chang M: Tamoxifen resistance in breast cancer. Biomol Ther (Seoul). 20:256–267. 2012. View Article : Google Scholar : PubMed/NCBI
7	Park M, Kim J, Phuong NTT, Park JG, Park JH, Kim YC, Baek MC, Lim SC and Kang KW: Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: Effects on small extracellular vesicles production. Sci Rep. 9:115872019. View Article : Google Scholar : PubMed/NCBI
8	De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, et al: 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Mol Oncol. 10:24–39. 2016. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Zhou C, Jiang H, Liang L, Shi W, Zhang Q, Sun P, Xiang R, Wang Y and Yang S: ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer. Cell Death Dis. 8:e27322017. View Article : Google Scholar : PubMed/NCBI
10	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
11	Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, Kang ZJ, Fan WJ, Zhu LL, Li M, et al: H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 8:e25692017. View Article : Google Scholar : PubMed/NCBI
12	Zhu QN, Wang G, Guo Y, Peng Y, Zhang R, Deng JL, Li ZX and Zhu YS: LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget. 8:91990–92003. 2017. View Article : Google Scholar : PubMed/NCBI
13	Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC and Raouf A: Long non-coding RNA H19 acts as an estrogen receptor modulator that is required for endocrine therapy resistance in ER+ breast cancer cells. Cell Physiol Biochem. 51:1518–1532. 2018. View Article : Google Scholar : PubMed/NCBI
14	Wu Y, Zhou Y, He J, Sun H and Jin Z: Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT. Int J Clin Exp Pathol. 12:2506–2515. 2019.PubMed/NCBI
15	Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, Yu W, Xu L, Zhao Y and Yu J: Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett. 469:310–322. 2020. View Article : Google Scholar : PubMed/NCBI
16	Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal. 10:eaak95572017. View Article : Google Scholar : PubMed/NCBI
17	Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Tan BK, Kumar AP and Sethi G: The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 20:2728–2769. 2015. View Article : Google Scholar : PubMed/NCBI
18	Cao L, Xiao X, Lei J, Duan W, Ma Q and Li W: Curcumin inhibits hypoxia-induced epithelial mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Oncol Rep. 35:3728–3734. 2016. View Article : Google Scholar : PubMed/NCBI
19	Gallardo M and Calaf GM: Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines. Int J Oncol. 49:1019–1027. 2016. View Article : Google Scholar : PubMed/NCBI
20	Li G, Wang Z, Chong T, Yang J, Li H and Chen H: Curcumin enhances the radiosensitivity of renal cancer cells by suppressing NF-κB signaling pathway. Biomed Pharmacother. 94:974–981. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y, Chen Y, Ying X, Chen C, Ye C, et al: The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 12:812019. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang Y, Shi J, Chai K, Ying X and Zhou BP: The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
24	Mills JN, Rutkovsky AC and Giordano A: Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 41:59–65. 2018. View Article : Google Scholar : PubMed/NCBI
25	Si H, Chen P, Li H and Wang X: Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer. Am J Transl Res. 11:3213–3225. 2019.PubMed/NCBI
26	Liao S, Yu C, Liu H, Zhang C, Li Y and Zhong X: Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin. OncoTargets Ther. 12:4099–4107. 2019. View Article : Google Scholar
27	Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta. 1833:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs. 185:191–203. 2007. View Article : Google Scholar : PubMed/NCBI
29	Al Khatib AM, Stepan AE, Margaritescu C, Simionescu C and Ciurea RN: E-cadherin and snail immunoexpression in colorectal adenocarcinomas. Curr Health Sci J. 45:204–209. 2019.PubMed/NCBI
30	Hu S, Xu Y, Meng L, Huang L and Sun H: Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med. 16:1266–1272. 2018.PubMed/NCBI
31	Cao MT, Liu HF, Liu ZG, Xiao P, Chen JJ, Tan Y, Jiang XX, Jiang ZC, Qiu Y, Huang HJ, et al: Curcumin downregulates the expression of Snail via suppressing Smad2 pathway to inhibit TGF-β1-induced epithelial-mesenchymal transitions in hepatoma cells. Oncotarget. 8:108498–108508. 2017. View Article : Google Scholar : PubMed/NCBI
32	Li W, Jiang Z, Xiao X, Wang Z, Wu Z, Ma Q and Cao L: Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Int J Oncol. 52:1593–1602. 2018.PubMed/NCBI